Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Takeda will soon report phase III results with its dengue fever vaccine, while Regenxbio needs an improvement with its cholesterol-lowering gene therapy candidate,…
The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.
One phase II success out of two has convinced Hvivo to push into pivotal trials with its universal flu vaccine candidate, but will potential partners be convinced?